Results 11 to 20 of about 90,077 (217)

Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma

Nature Communications, 2021
Immune-checkpoint blockade has shown limited benefits in patients with glioblastoma. To understand how the composition of the tumor immune microenvironment might limit clinical responses, here the authors present a high dimensional profiling of the ...
Alexander H. Lee, Lu Sun, Aaron Y. Mochizuki, Jeremy G. Reynoso, Joey Orpilla, Frances Chow, Jenny C. Kienzler, Richard G. Everson, David A. Nathanson, Steven J. Bensinger, Linda M. Liau, Timothy Cloughesy, Willy Hugo, Robert M. Prins   +13 more
doaj   +1 more source

The miRNA Profile of Inflammatory Colorectal Tumors Identify TGF-β as a Companion Target for Checkpoint Blockade Immunotherapy

Frontiers in Cell and Developmental Biology, 2021
Extrinsic factors such as expression of PD-L1 (programmed dealth-ligand 1) in the tumor microenvironment (TME) have been shown to correlate with responses to checkpoint blockade therapy.
Bjarne Bartlett, Bjarne Bartlett, Zitong Gao, Zitong Gao, Monique Schukking, Monique Schukking, Mark Menor, Vedbar S. Khadka, Muller Fabbri, Peiwen Fei, Youping Deng, Youping Deng   +11 more
doaj   +1 more source

The Application of Nanoparticle-Based Drug Delivery Systems in Checkpoint Blockade Cancer Immunotherapy

Journal of Immunology Research, 2018
Tumor is the most serious threat to human beings. Although war against cancer has been launched over forty years, cancer treatment is still far away from being satisfactory.
Huan Zhao, Yuanqi Li, Dan Wei, Hongrong Luo   +3 more
doaj   +1 more source

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma

Biomedicines, 2022
Malignant pleural mesothelioma (MPM) is a fatal cancer type that affects the membranes lining the lungs, and is causally associated with asbestos exposure. Until recently, the first-line treatment consisted of a combination of chemotherapeutics that only
Sophie Rovers, Annelies Janssens, Jo Raskin, Patrick Pauwels, Jan P. van Meerbeeck, Evelien Smits, Elly Marcq   +6 more
doaj   +1 more source

Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions

Journal for ImmunoTherapy of Cancer, 2020
Background Programmed cell death protein 1 (PD-1) and CTLA4 combination blockade enhances clinical efficacy in melanoma compared with targeting either checkpoint alone; however, clinical response improvement is coupled with increased risk of developing ...
Peng Yang, Wendy Blumenschein, David Bauché, Smita Mauze, Christina Kochel, Jeff Grein, Anandi Sawant, Yulia Zybina, Lakshmanan Annamalai, Jennifer H Yearley, Juha Punnonen, Edward P Bowman, Alissa Chackerian, Drake Laface   +13 more
doaj   +1 more source

Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy

Nanomaterials, 2021
Immune checkpoint receptor signaling pathways constitute a prominent class of “immune synapse,” a cell-to-cell connection that represses T-lymphocyte effector functions.
Chiara Cremolini, Emanuela Vitale, Raffaella Rastaldo, Claudia Giachino   +3 more
doaj   +1 more source

Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma

Frontiers in Oncology, 2019
Currently, the blockade of certain immune checkpoints such as the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1) using checkpoint inhibitors is standard of care in patients with metastatic melanoma, especially ...
Jan-Michael Werner, Viola Schweinsberg, Michael Schroeter, Michael Schroeter, Boris von Reutern, Michael P. Malter, Max Schlaak, Max Schlaak, Gereon R. Fink, Gereon R. Fink, Cornelia Mauch, Cornelia Mauch, Norbert Galldiks, Norbert Galldiks, Norbert Galldiks   +14 more
doaj   +1 more source

Metabolic Implications of Immune Checkpoint Proteins in Cancer

Cells, 2022
Expression of immune checkpoint proteins restrict immunosurveillance in the tumor microenvironment; thus, FDA-approved checkpoint inhibitor drugs, specifically PD-1/PD-L1 and CTLA-4 inhibitors, promote a cytotoxic antitumor immune response.
Elizabeth R. Stirling, Steven M. Bronson, Jessica D. Mackert, Katherine L. Cook, Pierre L. Triozzi, David R. Soto-Pantoja   +5 more
doaj   +1 more source

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment

Frontiers in Immunology, 2020
Advances in cancer immunity have promoted a major breakthrough in the field of cancer therapy. This is mainly associated with the successful development of immune checkpoint inhibitors (ICIs) for multiple types of human tumors.
Yuxiao Song, Yang Fu, Qi Xie, Bo Zhu, Jun Wang, Bicheng Zhang   +5 more
doaj   +1 more source

Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer

Neoplasia: An International Journal for Oncology Research, 2019
Immune checkpoint inhibitors have shown clinical benefit in several cancer entities including metastatic microsatellite instable colorectal carcinomas. However, for the majority of metastatic colorectal carcinomas the potential and limitations of immune ...
E Fiegle, D Doleschel, S Koletnik, A Rix, R Weiskirchen, E Borkham-Kamphorst, F Kiessling, W Lederle   +7 more
doaj   +1 more source